EUCTR2006-006913-34-DEActive, not recruitingNot Applicable
An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation Therapy
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Ferring Pharmaceuticals A/S
- Enrollment
- 568
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- Male
Inclusion Criteria
- •Patients with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated
- •Signed informed consent
- •The patients must have completed the FE 200486 CS21 study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •Patients with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated
- •Signed informed consent
- •The patients must have completed the FE 200486 CS21 study
Investigators
Similar Trials
Active, not recruiting
Not Applicable
An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation TherapyPatients with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated.MedDRA version: 9.1Level: LLTClassification code 10060862Term: Prostate cancerEUCTR2006-006913-34-NLFerring Pharmaceuticals A/S568
Active, not recruiting
Not Applicable
An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation TherapyPatients with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated.MedDRA version: 9.1Level: LLTClassification code 10060862Term: Prostate cancerEUCTR2006-006913-34-HUFerring Pharmaceuticals A/S568
Completed
Phase 3
An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation Therapy10038364prostate cancerNL-OMON31249Ferring5
Active, not recruiting
Phase 1
An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation TherapyPatients with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated.MedDRA version: 14.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2006-006913-34-GBFerring Pharmaceuticals A/S568
Active, not recruiting
Phase 1
An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation Therapy.Patients with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated.MedDRA version: 9.1Level: LLTClassification code 10060862Term: Prostate cancerEUCTR2006-006913-34-CZFerring Pharmaceuticals A/S557